SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Buhler A, Zenz T, Wenger MK, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980988.
  • 2
    Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: The need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 2005; 23: 488496.
  • 3
    Van Den Neste E, Letestu R, Aurran-Schleinitz T, Ysebaert L, Feugier P, Lepretre S, Dartigeas C. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: Where do we stand? Leuk Lymphoma 2012; 53: 362370.
  • 4
    Cabezudo E, Matutes E, Ramrattan M, Morilla R, Catovsky D. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997; 11: 19091914.
  • 5
    Cragg MS, Bayne MB, Tutt AL, French RR, Beers S, Glennie MJ, Illidge TM. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 2004; 104: 25402542.
  • 6
    Vuillier F, Claisse JF, Vandenvelde C, Travade P, Magnac C, Chevret S, Desablens B, Binet JL, Dighiero G. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992; 7: 195204.
  • 7
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 54465456.
  • 8
    Bottcher S, Ritgen M, Pott C, Bruggemann M, Raff T, Stilgenbauer S, Dohner H, Dreger P, Kneba M. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 16371645.
  • 9
    Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A, Campo E, Bosch F, Montserrat E. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 45634569.
  • 10
    Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 35143520.
  • 11
    Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Ona F. CD79b expression in B cell chronic lymphocytic leukemia: Its implication for minimal residual disease detection. Leukemia 1999; 13: 15011505.
  • 12
    Sanchez ML, Almeida J, Vidriales B, Lopez-Berges MC, Garcia-Marcos MA, Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: Basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002; 16: 14601469.
  • 13
    Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Apparent modulation of CD20 by rituximab: An alternative explanation. Blood 2004; 103: 39893990.
  • 14
    Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956964.
  • 15
    Durrieu F, Genevieve F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, et al. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up—A GEIL-GOELAMS study. Cytometry B Clin Cytom 2011; 80B: 346353.
  • 16
    Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 11641174.
  • 17
    Bottcher S, Stilgenbauer S, Busch R, Bruggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Dohner H, Hallek M, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: A comparative analysis. Leukemia 2009; 23: 20072017.